Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high‐risk follicular lymphoma: CALGB 50904 (Alliance)-Reference-Cited by-同舟云学术

Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high‐risk follicular lymphoma: CALGB 50904 (Alliance)

Published:2019-06-07 Issue:19 Volume:125 Page:3378-3389
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Blum Kristie A.¹²^ORCID,Polley Mei‐Yin³,Jung Sin‐Ho⁴,Dockter Travis J.³,Anderson Sarah³,Hsi Eric D.⁵,Wagner‐Johnston Nina⁶,Christian Beth²,Atkins Jim⁷,Cheson Bruce D.⁸,Leonard John P.⁹,Bartlett Nancy L.⁶

Affiliation:

1. Department of Hematology and Oncology Winship Cancer Institute, Emory University Atlanta Georgia

2. Comprehensive Cancer Center Ohio State University Columbus Ohio

3. Alliance Statistics and Data Center Mayo Clinic College of Medicine Rochester Minnesota

4. Department of Biostatistics and Bioinformatics Duke University Durham North Carolina

5. Department of Clinical Pathology Cleveland Clinic Cleveland Ohio

6. Siteman Cancer Center Washington University School of Medicine St. Louis Missouri

7. Southeast Clinical Oncology Research Consortium NCI Community Oncology Research Program Winston‐Salem North Carolina

8. Lombardi Comprehensive Cancer Center Georgetown University Hospital Washington DC

9. Department of Medicine and Meyer Cancer Center Weill Cornell Medicine New York New York

Funder

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32289

Reference20 articles.

1. Follicular Lymphoma International Prognostic Index

2. Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project

3. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

4. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

5. Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma;Blood Advances;2024-03-15

2. Lenalidomide, rituximab (R ² ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma;Leukemia & Lymphoma;2024-03-08

3. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01

4. Quantification of follow‐up time in oncology clinical trials with a time‐to‐event endpoint: Asking the right questions;Pharmaceutical Statistics;2023-03-27

5. Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials;Clinical Lymphoma Myeloma and Leukemia;2022-11